Amphotericin B causes nephrotoxicity as its major dose-limiting adverse effect. Liposomal amphotericin B (L-AMB) was developed to reduce this toxicity while maintaining antifungal efficacy. What is the molecular basis for L-AMB's improved renal safety profile?

• A Liposomes prevent amphotericin B from reaching the kidney entirely, redirecting 100% of drug to fungal tissues
• B Liposomal encapsulation reduces free plasma amphotericin B concentrations; the lipid bilayer of liposomes selectively transfers drug to fungal cell membranes (rich in ergosterol) rather than mammalian renal tubular cells (rich in cholesterol), reducing renal pore formation; liposomes also selectively accumulate in macrophage-rich tissues in fungal infection sites ✓
• C L-AMB forms larger aggregates in renal tubules that cannot enter cells, blocking nephrotoxicity via size exclusion
• D Liposomal formulation changes amphotericin B from its nephrotoxic form to a renal-protective aggregate that still kills fungi by a different mechanism

Explanation

Conventional amphotericin B deoxycholate (AmBD) is associated with nephrotoxicity through direct insertion into renal tubular cell membranes (via cholesterol-rich membranes) and renal vasoconstriction reducing GFR. Liposomal amphotericin B (LAMB) reduces toxicity through: (1) Lipid vehicles reduce free drug plasma concentration — less free drug available to interact with renal cells; (2) Preferential ergosterol-targeted drug delivery — the lipid formulation is more selectively extracted by ergosterol-rich fungal membranes compared to cholesterol-rich mammalian cell membranes; (3) Liposomes preferentially distribute to reticuloendothelial system (liver, spleen, macrophage-rich tissues) where invasive fungi reside, increasing efficacy at infection sites; (4) Reduced direct vasoconstrictive effect on renal afferent arterioles. Net result: much lower incidence of infusion-related reactions, nephrotoxicity, and electrolyte wasting.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.